This site is intended only for healthcare professionals resident in the Republic of Ireland
Short overview showing post HSCT survival outcomes with BESPONSA from INO-VATE long term follow-up and pooled analysis
Click here to view the key data from publication entitled, “Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database”
Explore BESPONSA outcomes and safety in RWE
Please click here to view the importance of transplant and VOD mitigation with BESPONSA in patients with R/R B-Cell ALL
Legal Category: S1A
Further information is available upon request
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023